Smiling man in an orange sweatshirt against a warm gray backdrop.

Actor portrayal

Think it solvable.

Cerenome connects precision diagnostics, targeted therapeutics, and clinical intelligence into an integrated central nervous system (CNS) oncology platform, designed to improve how CNS cancers are detected, treated, and understood.

A singular focus
on CNS cancers.

A brain or spinal cord cancer diagnosis still carries the weight of a different era. Fewer options, slower progress. A survival number that has barely moved while the rest of oncology research raced ahead. Cerenome exists to bend the survival curve, so that people live longer, healthier lives.

The 5-year survival rate for brain and other CNS cancers is just 33%, which has remained virtually unchanged in nearly 50 years.1

Primary CNS tumors are a clinically significant population, with 26,710 new cases expected in 2026.2

Metastatic CNS cancers are a large, growing, and clinically underserved population. Up to 40% of adults with cancer develop brain metastases.3

1. National Cancer Institute. SEER Cancer Stat Facts: Brain and Other Nervous System Cancer. National Institutes of Health. 2. Central Brain Tumor Registry of the United States (CBTRUS), 2025 Statistical Report. 3. Nabors LB, Ammirati M, Bierman PJ, et al. Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013;11(9):1114-1151. doi:10.6004/jnccn.2013.0132

The Platform

How we’re changing CNS cancer care.

CNS cancers demand more than isolated innovations. They require a connected approach, where detection, treatment, and learning make each other stronger. That is our platform: three capabilities, one system.

Diagnostics

See what imaging and CSF cytology may miss.

Powered by CNSide®, cellular and molecular clarity from a single cerebrospinal fluid sample.

Therapeutics

Target the cancer, preserve the healthy tissue.

Led by REYOBIQ™, targeted radiation delivers where most therapies can’t reach.

Data Insights

Smarter with every case.

A data layer that turns every result into sharper care over time.

Our Portfolio

Building for the hardest diagnoses in CNS cancer.

Recurrent glioblastoma. Leptomeningeal metastases. Pediatric brain cancer. Three trials of an investigational radiotherapy delivered directly into the central nervous system, in cancers where treatment options remain limited.

Researcher examining a sample under a microscope in a lab
Helaine Bader, Founder of the Leptomeningeal Cancer Foundation

“We need to make sure people know there are better tests. There are clinical trials. There are options for them.”

Helaine Bader
Founder and President of the Leptomeningeal Cancer Foundation

Inside Cerenome

The team making CNS cancers solvable.

From our campus in the medical hub of Houston, a focused team of scientists, clinicians, engineers, and technicians, working toward one vision: a world where CNS cancers are manageable diseases.

The Latest

News, science, and investor updates.

Publications, presentations, and press releases, updated as the work advances.

NASDAQ CM: CNSY

$0.95

+0.18 (+23.32%) Data provided by NASDAQ.
Nov 13, 2026 3:00 PM CST
Minimum 15 minutes delayed. Source: LSEG